Korean Market
EXCH
Aprogen
★★

Aprogen Terminates Exclusive License Agreement with Parmesin for Immune Anticancer Drug, Receives Refund of Down Payment and Penalty

 
EXCH
Aprogen
★

Aprogen's subsidiary issues 50.8B won CB to repay affiliate debt, risks 93% dilution of subsidiary shares

 
EXCH
Aprogen
★★

Aprogen Faces Shareholder Value Concerns Due to Persistent Losses and Governance Deficiencies

 
OWNR
Aprogen
★

Aprogen's Largest Shareholder Stake Rises to 74.13%... CB Acquisitions Strengthen Control, Potential Dilution Risk

 
EXCH
Aprogen
★

Aprogen Completes 10 Billion Won Convertible Bond Issuance…Dilution Risk Persists

 
EXCH
Aprogen
★★★★

Subsidiary Aprogen Biologics Issues 50.8 Billion Won CB with Discounted Conversion Price, Combined with Existing CBs to Create 262% Dilution Risk

 
OWNR
Aprogen
★

Aprogen Largest Shareholder G-Baise Maintains 71.98% Stake, Major Contract Shares Rise to 33.24%

 
EXCH
Aprogen
★

Aprogen decides to acquire 10 billion won CB of subsidiary Aprogen Biologics

 
MATR
Aprogen
★★

10B won CB Issuance with Conversion at 5,350 won (31% premium); Existing CBs Lead to 148% Potential Dilution

 
MATR
Aprogen
★

Convertible Bond Issuance Decision (Specific Terms Not Disclosed)

 
EXCH
Aprogen
★

KRW 12 Billion Third-Party Rights Offering for Aprogen Share Acquisition

 
EXCH
Aprogen
★

Aptocrom Changes Third-Party Allotment Target for 12 Billion Won Capital Increase to Acquire Securities

 
EXCH
Aprogen
★

Aptn to Issue 21M Shares in Third-Party Placement (Payment, Listing Delayed)

 
OWNR
Aprogen
★

Large Shareholding Report Filed (Influence on Management)

 
PERI
Aprogen
★

Aprogen Q1 2026: Continued Losses and Capital Reduction Plan